By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
LATEST POSTS
- 1
\Step by step instructions to Pick the Best Material Organization for Your Home\ - 2Kona SUV: The Courageous Minimized That is Catching Hearts Around the world
- 3Rio Tinto resumes operations at three Pilbara port terminals after cyclone Narelle
- 4Bennu asteroid samples provide clues about solar system origins and 'space gum'
- 5Zelensky sees new Russian attack threat from Belarus
- 'You're no longer my sister' - rows erupt as war divides Iranian families
- Mississippi Insight for Jan. 11, 2026
- Pick Your Favored kind of books
- Josh Duhamel's secret to the good life at 53? Wolverine peptides, ditching Hollywood and having another baby.
- IDF drops over 80 explosives on Tehran weapon production sites in latest strike
- Deadly heat worldwide prompts $300 million for climate health research at COP30
- US FDA approves Kura-Kyowa's blood cancer therapy
- Becoming Familiar with an Unknown dialect: My Language Learning Excursion
- Improving as a Cook: Culinary Experiences in the Kitchen
